CD4+ Cell Depletion in Allogeneic Stem Cell Transplantation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Allogeneic hematopoietic stem cell transplantation for tumors is limited by the risk of graft-versus-host disease (GVHD) and delayed immune reconstitution, leading to infections and complications, with no established effective treatments for the latter.

Innovation Solution

A prophylactic agent that depletes CD4+ cells using a CD4 antibody or its modified form is administered to promote immunological reconstitution and prevent infections, maintaining the graft-versus-tumor effect while reducing GVHD-related complications.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If allogeneic hematopoietic stem cell transplantation is performed to achieve graft-versus-tumor effect, then anti-tumor efficacy is improved, but graft-versus-host disease and delayed immune reconstitution occur

Engineering Contradiction:

Improveanti-tumor efficacyVSAvoidgraft-versus-host disease and infection risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention extracts and removes CD4+ T cells from the donor stem cell preparation through immunomagnetic separation or flow cytometry sorting, thereby eliminating the harmful components (CD4+ cells that cause GVHD) while preserving the beneficial components (stem cells and other immune cells) for transplantation

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention changes the cellular composition parameter of the transplant material by depleting CD4+ cells to specific levels (reducing CD4+ cell content to 5% or less, preferably 1% or less of total nucleated cells), thereby modifying the immunological profile to reduce GVHD risk while maintaining GVT effect

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If immunosuppressants are administered to prevent graft-versus-host disease, then GVHD severity is reduced, but immune reconstitution is further delayed

Engineering Contradiction:

ImproveGVHD severityVSAvoidimmune reconstitution time

Core Design Contradiction:

Object-affected harmful factorsVSDuration of action of stationary object

Solution Approach 1:

The invention performs preliminary depletion of CD4+ cells in the donor stem cell preparation before transplantation, thereby preventing GVHD from occurring in the first place rather than treating it after onset, which avoids the need for post-transplant immunosuppression and its associated delays in immune reconstitution

Inventive Principle:

Principle #10Preliminary action

3Object-affected harmful factors

If CD4+ cells are depleted to prevent GVHD and promote immune reconstitution, then infection risk is reduced, but graft-versus-tumor effect may be compromised

Engineering Contradiction:

Improveinfection riskVSAvoidgraft-versus-tumor effect

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The invention selectively extracts only CD4+ T cells from the donor cell population using CD4-specific antibodies conjugated to magnetic beads or fluorochromes, thereby removing the harmful subset (CD4+ cells) while preserving other beneficial cells including CD8+ T cells, NK cells, and hematopoietic stem cells that mediate the GVT effect

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention applies selective depletion only to the CD4+ cell compartment while leaving other immune cell compartments intact, thereby creating a non-uniform cellular composition that specifically reduces GVHD and infection risk while preserving the multifaceted mechanisms of tumor rejection

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The CD4+ cell-depleting agent effectively promotes early immune reconstitution, reduces infection risk, and maintains the graft-versus-tumor effect, enabling safer and more widespread use of allogeneic hematopoietic stem cell transplantation therapy.

Implementation Method 1

a substance capable of depleting CD4 positive cells... comprising a CD4 antibody or an altered and/or modified form

Methodology Applied

Scientific EffectAntigen-antibody binding:

Data Source

PatentUS9156912B2Immunological reconstitution promoter or prophylactic agent for infections each of which maintains graft-versus-tumor effect

Publication Date: 2015.10.13 KOUJI MATSUSHIMA

AI summary

The object of the invention is to provide an immunological reconstitution promoter or a prophylactic agent for infections for use in allogeneic hematopoietic stem cell transplantation therapy for tumors. The promoter or prophylactic agent enables the amelioration of delayed immune reconstitution or the prevention of infection following transplantation, while maintaining the GVT effect of allogeneic hematopoietic stem cell transplantation. Specifically, in a transplant patient in whom immune reconstitution is delayed, such reconstitution can be promoted by administering, at an early stage following transplantation, a substance capable of depleting CD4+ cells. Early completion of infection management in the patient and improvement in the survival rate are anticipated as a result. In addition, the risk of complications associated with allogeneic hematopoietic stem cell transplantation is reduced, enabling more widespread use of this therapy.